Screener
PTC Therapeutics PTCT Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Finance lease liabilities- noncurrent | — | 3,000 |
| Liability for sale of future royalties- noncurrent | 2,022,189 | 2,025,366 |
| Other long-term liabilities | 13,704 | 13,704 |
| Total liabilities | 3,049,569 | 3,104,080 |
| Stockholders’ deficit: | ||
| Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 82,882,024 shares at March 31, 2026. Authorized 250,000,000 shares; issued and outstanding 81,474,366 shares at December 31, 2025. | 81 | 80 |
| Additional paid-in capital | 2,778,026 | 2,748,335 |
| Accumulated other comprehensive income | 8,466 | 10,501 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's total liabilities?
- PTC Therapeutics (PTCT) reported total liabilities of $3.05B in Q1 2026.
- How has PTC Therapeutics's total liabilities changed year-over-year?
- PTC Therapeutics's total liabilities increased by 7.3% year-over-year, from $2.84B to $3.05B.
- What is the long-term trend for PTC Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), PTC Therapeutics's total liabilities has grown at a 12.5% compound annual growth rate (CAGR), from $1.73B to $3.1B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about PTC Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude